



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	3
-------	---	----	---

Application Number	10/700,816-Conf. #9864
Filing Date	November 4, 2003
First Named Inventor	Zuoshang XU
Art Unit	1635
Examiner Name	S. McGarry
Attorney Docket Number	UMY-038

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that citation was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

837279-1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/700,816-Conf. #9864
				Filing Date	November 4, 2003
				First Named Inventor	Zuoshang XU
				Art Unit	1635
				Examiner Name	S. McGarry
Sheet	2	of	3	Attorney Docket Number	UMY-038

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Pending Claims for UMY-041	
	C2	Fressinaud, Edith et al., "Molecular Genetics of Type 2 von Willebrand Disease," <i>International Journal of Hematology</i> , Vol. 75:9-18 (2002)	
	C3	Gualberto, Antonio et al., "An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95:5166-5171 (1998)	
	C4	Hirota, Seiichi et al., "Gain-of-function Mutation at the extracellular domain of KIT in gastrointestinal stromal tumours," <i>Journal of Pathology</i> , Vol. 193:505-510 (2001)	
	C5	Hixon, M.L. et al., "Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint," <i>Histol. Histopathol.</i> , Vol. 15:551-556 (2000)	
	C6	Ho, L.W. et al., "The molecular biology of Huntington's Disease," <i>Psychological Medicine</i> , Vol. 31:3-14 (2001)	
	C7	Hojo, S. et al., "Heterogeneous point mutations of the p53 gene in pulmonary fibrosis," <i>Eur. Respir. J.</i> , Vol. 12:1404-1408 (1998)	
	C8	Kopp, P., "Human Genome and Diseases: Review, The TSH receptor and its role in thyroid disease," <i>CMLS, Cell. Mol. Life Sci.</i> , Vol. 58:1301-1322 (2001)	
	C9	Kosaki, Kenjiro et al., "PTPN11 (Protein-Tyrosine Phosphatase, Nonreceptor-Type II) Mutations in Seven Japanese Patients with Noonan Syndrome," <i>The Journal of Clinical Endocrinology & Metabolism</i> , Vol. 87(8):3529-3533 (2002)	
	C10	Lania, Andrea et al., "G protein mutations in endocrine diseases," <i>European Journal of Endocrinology</i> , Vol. 145:543-559 (2001)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08b (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/700,816-Conf. #9864		
		Filing Date	November 4, 2003		
		First Named Inventor	Zuoshang XU		
		Art Unit	1635		
		Examiner Name	S. McGarry		
Sheet	3	of	3	Attorney Docket Number	UMY-038

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C11	Müller, Jörn et al., "Severe testotoxicosis phenotype associated with ASP578→Tyr mutation of the lutrophin/choriogonadotrophin receptor gene," <i>J. Med. Genet.</i> , Vol. 35:340-341 (1998)	
	C12	Oldridge, Michael et al., "Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B," <i>Nature Genetics</i> , Vol. 24:275-278 (2000)	
	C13	Saenger, Wolfram, "Principles of Nucleic Acid Structure," Springer-Verlag, Charles R. Cantor, Editor (1983)	
	C14	Sahin-Tóth, Miklós et al., "Gain-of-Function Mutations Associated with Hereditary Pancreatitis Enhance Autoactivation of Human Cationic Trypsinogen," <i>Biochemical and Biophysical Research Communications</i> , Vol. 278:286-289 (2000)	
	C15	Simon, E.S. et al., "Creutzfeldt-Jakob Disease Profile in Patients Homozygous for the PRNP E200K Mutation," <i>Ann. Neurol.</i> , Vol. 47:257-260 (2000)	
	C16	Zuccato, Chiara et al., "Loss of Huntington-Mediated BDNF Gene Transcription in Huntington's Disease," <i>Science</i> , Vol. 293:493-498 (2001)	
	C17	Office Action mailed 05/27/05 for USSN 10/715,229 (Inventor: Tariq M. Rana)	
	C18	Office Action mailed 08/15/06 for USSN 10/715,229 (Inventor: Tariq M. Rana)	
	C19	Office Action mailed 04/02/07 for USSN 10/715,229 (Inventor: Tariq M. Rana)	
	C20	Office Action mailed 12/11/07 for USSN 10/715,229 (Inventor: Tariq M. Rana)	
	C21	Office Action mailed 10/20/08 for USSN 11/698,689 (Inventor: Aronin et al)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.